Last reviewed · How we verify
Orca Biosystems, Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Orca-T | Orca-T | phase 3 | PD-1 inhibitor | PD-1 | Oncology |
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- ASLAN Pharmaceuticals · 1 shared drug class
- ATGC Co., Ltd. · 1 shared drug class
- Addpharma Inc. · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Akeso · 1 shared drug class
- Amgen · 1 shared drug class
- Asahi Kasei Pharma Corporation · 1 shared drug class
- 3D Medicines (Sichuan) Co., Ltd. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Orca Biosystems, Inc.:
- Orca Biosystems, Inc. pipeline updates — RSS
- Orca Biosystems, Inc. pipeline updates — Atom
- Orca Biosystems, Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Orca Biosystems, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/orca-biosystems-inc. Accessed 2026-05-15.